{"result": "(\"entity\"<|>COR-I STUDY GROUP<|>ORGANIZATION<|>The COR-I Study Group is a research group that conducted a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial on the effects of naltrexone plus bupropion on weight loss in overweight and obese adults.)\n##\n(\"entity\"<|>COR-II STUDY GROUP<|>ORGANIZATION<|>The COR-II Study Group is a research group that conducted a randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors.)\n##\n(\"entity\"<|>COR-DIABETES STUDY GROUP<|>ORGANIZATION<|>The COR-Diabetes Study Group is a research group that studied the effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.)\n##\n(\"entity\"<|>LEADER TRIAL INVESTIGATORS<|>ORGANIZATION<|>The LEADER Trial Investigators are a group of researchers who conducted a study on liraglutide and its cardiovascular outcomes in patients with type 2 diabetes.)\n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>JAMA is a peer-reviewed medical journal that published the SCALE Diabetes randomized clinical trial.)\n##\n(\"entity\"<|>NEW ENGLAND JOURNAL OF MEDICINE<|>ORGANIZATION<|>The New England Journal of Medicine is a prestigious medical journal that published various studies related to obesity and diabetes treatments.)\n##\n(\"entity\"<|>LIRAGLUTIDE<|>EVENT<|>Liraglutide is a medication used for weight management and diabetes treatment, studied in various clinical trials for its efficacy.)\n##\n(\"entity\"<|>NALTREXONE<|>EVENT<|>Naltrexone is a medication that, in combination with bupropion, was studied for its effects on weight loss in clinical trials.)\n##\n(\"entity\"<|>BUPROPION<|>EVENT<|>Bupropion is an antidepressant that was studied in combination with naltrexone for weight loss in overweight and obese adults.)\n##\n(\"entity\"<|>OBESITY<|>EVENT<|>Obesity is a medical condition that was the focus of multiple clinical trials aimed at finding effective treatments.)\n##\n(\"entity\"<|>TYPE 2 DIABETES<|>EVENT<|>Type 2 diabetes is a chronic condition that was studied in relation to weight loss and medication efficacy in various trials.)\n##\n(\"relationship\"<|>COR-I STUDY GROUP<|>LIRAGLUTIDE<|>The COR-I Study Group conducted trials that included the study of liraglutide for weight management<|>7)\n##\n(\"relationship\"<|>COR-II STUDY GROUP<|>NALTREXONE<|>The COR-II Study Group studied the effects of naltrexone in a clinical trial focused on weight loss<|>7)\n##\n(\"relationship\"<|>COR-DIABETES STUDY GROUP<|>TYPE 2 DIABETES<|>The COR-Diabetes Study Group focused on the effects of treatments for obesity in patients with type 2 diabetes<|>8)\n##\n(\"relationship\"<|>LEADER TRIAL INVESTIGATORS<|>LIRAGLUTIDE<|>The LEADER Trial Investigators studied the cardiovascular outcomes of liraglutide in type 2 diabetes patients<|>9)\n##\n(\"relationship\"<|>JAMA<|>COR-II STUDY GROUP<|>JAMA published the findings of the COR-II Study Group regarding naltrexone and bupropion<|>8)\n##\n(\"relationship\"<|>NEW ENGLAND JOURNAL OF MEDICINE<|>LIRAGLUTIDE<|>The New England Journal of Medicine published studies related to liraglutide and its effects on weight loss<|>8)\n##\n(\"relationship\"<|>NALTREXONE<|>BUPROPION<|>Naltrexone and bupropion were studied together for their combined effects on weight loss<|>9)\n##\n(\"relationship\"<|>OBESITY<|>TYPE 2 DIABETES<|>Obesity is a significant risk factor for the development of type 2 diabetes, which was a focus of several studies<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Contro-\n      McKenney J, O’Neil PM. Bupropion SR enhances                          lled Trial of 3.0 mg of Liraglutide in Weight Mana-\n      weight     loss:   a   48-week      double-blind,       place-        gement. New Engl J Med. 2015; 373:11-22.\n      bo-controlled trial. Obes Res 2002; 10: 633-641.                 27.  Davies MJ, Bergenstal R, Bode B, Kushner RF,\n17.   Greenway FL, Fujioka K, Plodkowski RA, Mudaliar                       Lewin A, Vang Skjøth T, et al. Efficacy of liraglutide\n      S, Guttadaira M, Erikson J, Kim DD, Dunayevich E,                     for weight loss among patients with type 2 diabe-\n      for the COR-I Study Group. Effect of naltrexone                       tes. The SCALE Diabetes randomized clinical trial.\n      plus bupropion on weight loss in overweight and                       JAMA. 2015; 14:687-99.\n      obese adults (COR-I): a multicentre, randomised,                 28.  Wadden TA, Hollander P, Klein S, Niswender S, Woo\n      double-blind, placebo-controlled, phase 3 trial.                      V, Hale PM, et al. Weight maintenance and additio-\n      Lancet. 2010; 376: 595-605.                                           nal   weight     loss  with    liraglutide   after   low-calo-\n18.   Apovian CM, Aronne L, Rubino D,Still C, Wyatt H,                      rie-diet-induced weight loss: The SCALE Maintenan-\n      Burns C, et al;COR-II Study Group. A randomized,                      ce randomized study. Int J Obes. 2013; 37: 1443-51.\n      phase 3 trial ofnaltrexone SR/bupropion SR on                    29.  Blackman A, Foster GD, Zammit G, Rosenberg R,\n      weight     andobesity-related       risk  factors    (COR-II).        Aronne L, Wadden T. et al. Effect of liraglutide\n      Obesity (SilverSpring). 2013; 21:935-943.                             3.0mg in individuals with obesity and moderate or\n19.   Hollander P, Gupta AK, Plodkowski R,Greenway F,                       severe obstructive sleep apnea: the SCALE Sleep.\n      Bays H, Burns C, et al;COR-Diabetes Study Group.                      Apnea randomized clinical trial. Int J Obes. 2016;\n      Effects of naltrexonesustained-release/bupropion                      40:1310-9.\n      sustained-releasecombination            therapy     on   body    30.  Marso SP, Daniels GH, Brown-Frandsen K, Kristen-\n      weight     and    glycemicparameters         in  overweight           sen P, Mann JF, LEADER Trial Investigators. Liraglu-\n      and obese patients withtype 2 diabetes. Diabetes                      tide and Cardiovascular Outcomes in Type 2 Dia-\n      Care. 2013; 36:4022-4029.                                             betes. N Engl J Med. 2016 28; 375: 311-22.\n20.   Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S,               31.  Fujioka K, O’Neil PM, Davies M, Greenway F, C W\n      O’Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erick-                    Lau D, Claudius B, et al. Early Weight Loss with Li-\n      son JS, Maier HN, Kim DD, Dunayevich E. Weight                        raglutide 3.0 mg Predicts 1-Year Weight Loss and\n      loss with naltrexone SR/bupropion SR combination                      is Associated with Improvements in Clinical Mar-\n      therapy as an adjunct to behavior modification:                       kers. Obesity (Silver Spring). 2016; 24:2278-2288.\n      the COR-BMOD trial. Obesity (Silver Spring). 2011;               32.  Kopelman P, Groot GH, Rissanen A, Rossner S,\n      19:110-120.                                                           Toubro S, Palmer R, Hallam R, Bryson A, Hickling\n21.   Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB,                    RI. Weight loss, HbA1c reduction, and tolerability\n      Bakris G, et al. Effect of Naltrexone-Bupropion on                    of cetilistat in a randomized, placebo-controlled\n---\n                                                                 Tema 8.     Tratamiento farmacológico de la obesidad        141\n\n\n\n     phase 2 trial in obese diabetics: comparison with             36.   Bhat VK, Kerr BD, Flatt PR, Gault VA.A novel\n     orlistat (Xenical). Obesity. 2010; 18:108-15.                       GIP-oxyntomodulin hybrid peptide acting through\n33.  Astrup A, Madsbad S, Breum L, Jensen TJ, Krous-                     GIP, glucagon and GLP-1 receptors exhibits weight\n     trup JP, Larsen TM. Effect of tesof\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}